4-氯-alpha-(4-氯苯基)苯甲胺 | 14212-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-alpha-(4-氯苯基)苯甲胺
• 英文名称: bis(4-chlorophenyl)methanamine
• 英文别名: bis(4-chlorophenyl)methylamine；4,4'-Dichlorobenzhydrylamine；di-p-chlorobenzhydrylamine；4,4'-dichloro-benzhydrylamine；4,4'-Dichlor-benzhydrylamin；[bis(4-chloro-phenyl)methyl]amine；4-Chloro-alpha-(4-chlorophenyl)benzenemethanamine
• CAS: 14212-38-5
• 化学式: C₁₃H₁₁Cl₂N
• mdl: MFCD11127107
• 分子量: 252.143
• InChiKey: XJEIUGUQDIKUSM-UHFFFAOYSA-N

物化性质

• 熔点：
  133-136 °C
• 沸点：
  370.6±32.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-氯-alpha-(4-氯苯基)苯甲胺 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 17β-N-bis<<(4-chlorophenyl)methyl>carbamoyl>-6-azaandrost-4-en-3-one
  参考文献：
  名称：

  6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase

  摘要：

  6-Azaandrost-4-en-3-ones were synthesized and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-Delta(5)-steroid dehydrogenase/3-keto-Delta(5)-steroid isomerase (3BHSD) to explore the structure-activity relationship of this novel series in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Compounds with picomolar IC50's versus human type 2 5AR and low nanomolar K-i's versus human type 1 5AR with 100-fold selectivity versus 3BHSD were identified (70). Preliminary in vivo evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor-induced prostate involution and dog pharmacokinetic measurements identified a series of 17 beta-[N-(diphenylmethyl)carbamoyl]-6-azaandrost-4-en-3-ones (compounds 54, 66, and 67) with good in vivo efficacy and half-life in the dog. Inhibitors with, at the minimum, low nanomolar potency toward both human 5AR's and selectivity versus 3BHSD may show advantages over previously known 5AR inhibitors in the treatment of disease states which depend upon dihydrotestosterone, such as benign prostatic hyperplasia.

  DOI：

  10.1021/jm00041a014
• 作为产物：
  描述：

  N-[二(4-氯苯基)亚甲基]羟胺 在 ammonium hydroxide 、 ammonium acetate 、 锌 作用下， 以 乙醇 为溶剂， 生成 4-氯-alpha-(4-氯苯基)苯甲胺
  参考文献：
  名称：

  Cobalt‐Catalyzed Enantioselective C−H Carbonylation towards Chiral Isoindolinones

  摘要：

  摘要过渡金属催化的对映体选择性C-H羰基化反应与一氧化碳--一种重要且容易获得的C1原料--仍然具有挑战性。在此，我们揭示了一种前所未有的由廉价易得的钴（II）盐催化的对映体选择性 C-H 羰基化反应。反应通过非对称化、动力学解析和平行动力学解析高效地进行，以良好的产率和优异的对映选择性（高达 92% 的产率和 99% 的ee）获得了多种手性异吲哚啉酮。通过不对称合成生物活性化合物，如(S)-PD172938 和 (S)-Pazinaclone，证明了该方法的合成潜力。所得手性异吲哚啉酮还可作为手性配体，在钴催化下与炔烃进行对映选择性 C-H 环化反应，构建磷立体中心。

  DOI：

  10.1002/anie.202318803

文献信息

• [EN] PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE PYRAZOLE SERVANT DE MODULATEURS DE PROTEINE KINASE
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005061463A1

  公开（公告）日：2005-07-07

  The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

  该发明提供了具有蛋白激酶B抑制活性的化合物，其化学式为：（I），其中A是一个饱和的含有1至7个碳原子的烷基链连接基团，该连接基团在R1和NR2R3之间延伸的最大链长为5个原子，在E和NR2R3之间延伸的最大链长为4个原子，其中连接基团中的一个碳原子可以选择性地被氧原子或氮原子取代；连接基团A的碳原子可以选择性地携带来自酮基、氟和羟基的一个或多个取代基，前提是当存在羟基时，该羟基不位于相对于NR2R3基团的碳原子a处，且当存在酮基时，该酮基位于相对于NR2R3基团的碳原子a处；E是一个单环或双环的碳环或杂环基团；R1是芳基或杂芳基团；R2、R3、R4和R5如权利要求中所定义。还提供了含有这些化合物的药物组合物，制备这些化合物的方法以及它们作为抗癌剂的用途。
• PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS
  申请人：Thompson Neil Thomas

  公开号：US20100166699A1

  公开（公告）日：2010-07-01

  The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.

  该发明提供了一种组合物，包括一个辅助化合物（例如一个、两个或更多个辅助化合物）和具有蛋白激酶B抑制活性的式（I）化合物：其中A是含有1至7个碳原子的饱和碳氢链连接基团，连接基团在R1和NR2R3之间延伸的最大链长为5个原子，在E和NR2R3之间延伸的最大链长为4个原子，其中连接基团中的一个碳原子可以选择性地被氧原子或氮原子取代；连接基团A的碳原子可以选择性地携带来自酮基、氟和羟基的一个或多个取代基，前提是当羟基存在时，不位于相对于NR2R3基团的碳原子a处，且当酮基存在时，位于相对于NR2R3基团的碳原子a处；E是单环或双环碳环或杂环基团；R是芳基或杂芳基团；R2、R3、R4和R5如权利要求中所定义。还提供了患者包装、药物配套和包装以及含有这些组合物的组合物、制备这些组合物的方法以及它们作为抗癌剂的联合治疗中的用途。
• [EN] ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] ACYLGUANIDINES COMME INHIBITEURS DE LA TRYPTOPHAN HYDROXYLASE
  申请人：KAROS PHARMACEUTICALS INC

  公开号：WO2015089137A1

  公开（公告）日：2015-06-18

  The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及酰基胍，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPHl），在治疗与外周血清素有关的疾病或紊乱方面具有用处，例如胃肠道、心血管、肺部、炎症、代谢和骨量低等疾病，以及血清素综合征和癌症。
• Kinetic Resolution of β-Alkenyl-, β-Alkynyl- and β-Flavenyl-Substituted β-Hydroxy Esters in Asymmetric Dehydration
  作者：Min Hee Lee、Eui Ta Choi、Dajung Kim、Yoon Min Lee、Yong Sun Park

  DOI：10.1002/ejoc.200800807

  日期：2008.11

  Catalytic asymmetric dehydration of β-alkenyl- or alkynyl-substituted β-hydroxy esters by kinetic resolution has been investigated with five different chiral ligands 3–7. The kinetic resolution of a variety of racemic β-hydroxy tert-butyl esters in the presence of a prolinol chiral ligand and BrZnCH2CO2tBu provided highly enantio-enriched β-hydroxy esters 9–22 with selectivity factors ranging from

  已经使用五种不同的手性配体 3-7 研究了通过动力学拆分对 β-烯基或炔基取代的 β-羟基酯进行催化不对称脱水。在脯氨醇手性配体和 BrZnCH2CO2tBu 存在下，多种外消旋 β-羟基叔丁酯的动力学拆分提供了高度对映体富集的 β-羟基酯 9-22，选择性因子范围为 11 到 59。此外，证明了这种不对称合成方法在制备富含对映体的黄酮衍生物 23-29 中的应用。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
• [EN] SUBSTITTUED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE<br/>[FR] PYRIDINES SUBSTITUÉES UTILISÉES COMME INHIBITEURS DE LA HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016054806A1

  公开（公告）日：2016-04-14

  The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

  本发明涉及一种化合物，其化学式为I，该化合物抑制HIF脯氨酸羟化酶，可用于增强内源性促红细胞生成素的产生，用于治疗与内源性促红细胞生成素减少相关的疾病，如贫血和类似疾病，以及包含该化合物和药用载体的药物组合物。